New Delhi: In a big move, Bharat Biotech’s Covaxin has reportedly received approval from Subject Expert Committee (SEC) on COVID-19 for emergency use in children above 2 years in India.
The SEC has submitted recommendations to Drugs Controller General of India (DCGI) for approval of the vaccine for use on children, stated reports.
Once approved, Covaxin will become only second vaccine cleared for use on kids and the only such vaccine for toddlers too. In August, Zydus Cadilla’s three-dose DNA jab was allowed to be used on adults and children over 12.
The Hyderabad-based company had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September.
A third potential vaccine for kids is Serum Institute’s Novavax, for which the DCGI last month cleared trials for children between seven and 11 years.
Bhubaneswar: An IT engineer was arrested by the Commissionerate Police on Friday on charges of…
Bhubaneswar: The Odisha Vigilance sleuths on Friday apprehended medical officer in-charge of Boipariguda Community Health…
New Delhi: Men should not tailor clothes for women or cut a woman’s hair either,…
Bhubaneswar: Driver of a bus died and over 30 passengers sustained injuries as the vehicle…
New Delhi: The rupee fell 5 paise to an all-time low of 84.37 against the…
Srinagar: For the third day in a row, the Jammu and Kashmir assembly on Friday…
Berhampur: A video of a Royal Bengal Tiger (RBT), which was spotted crossing the National…
New Delhi: Anita Lallian, a real estate developer and film producer with Indian roots has…